• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>PML

Related Topics

  1. PIMCO Municipal Income II
  2. Facebook
  3. M & T Bank
  4. LinkedIn
  5. Securities Exchange Commission
  6. Social Media

Popular Topics

  1. Hormel Foods
  2. FLIR Systems
  3. John Wiley & Sons
  4. Middle East
  5. Caribbean

PML

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Elan Advises Shareholders to Withdraw Any Acceptances of the Royalty Pharma Offer and Not to Tender Any Further Acceptances into This Lapsed Offer*

    Elan Advises Shareholders to Withdraw Any Acceptances of the Royalty Pharma Offer and Not to Tender Any Further Acceptances into This Lapsed Offer*

  2. Elan Board Of Directors Unanimously And Without Reservation Rejects Royalty Pharma's Revised Tender Offer

    Elan Board Of Directors Unanimously And Without Reservation Rejects Royalty Pharma's Revised Tender Offer

  3. Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting

    Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting

  4. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA

    Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA

  5. Elan Issues Response Document Further Detailing Inadequacy of Royalty Pharma's Revised Offer

    Elan Issues Response Document Further Detailing Inadequacy of Royalty Pharma's Revised Offer

  6. Elan Announces Transactions: Decisively Transforming the Company

    Elan Announces Transactions: Decisively Transforming the Company

  7. Present and Emerging Risks to the Gold Trade

     

  8. Year in Review: Municipal CEFs

    We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.

  9. A Closer Look at CEF Duration Risk

    An examination of 10 CEFs with the highest duration risk.

Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.